In April of this year, Takeda Pharmaceutical, Japan’s largest drug company purchased Millennium Pharmaceuticals, one of the earliest American genomics companies for nearly $9 billion providing Takeda an entry into the cancer-drug market. During this off-the-record discussion, topics will include:
- Important criteria each company sought in a strategic partner
- Communicating effectively through cultural differences
- Lessons learned during the due diligence process
- Approach for successful integration of the two companies
Presenters included:
- Gabor Garai, Co-Chair, Life Sciences Industry Team, Foley
- Dr. Daniel Curran, Vice President, Corporate Development, Millennium Pharmaceuticals Inc.
- Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America, Inc.
Related Insights
June 23, 2025
Labor & Employment Law Perspectives
First Circuit Concludes Employee’s Wrongful Termination, Other State Law Claims are Preempted by Federal Law
The U.S Court of Appeals for the First Circuit (covering Maine, Massachusetts, New Hampshire, Puerto Rico, and Rhode Island) recently…
June 4, 2025
Events
Selecting the Right Trustee and Role of Trust Protectors within the Trust World
June 20, 2025
Events
Wealthyist E25 | Philanthropy Trends: An Interview With Jason Kohout, Chair – Family Offices Team, Foley & Lardner
Jason Kohout, Chair of the Family Office area at Foley and Lardner and director of the Wisconsin Philanthropy Network joins Annex Private Client Wealth Strategist Brian Lamborne in episode 25 of “Wealthyist.”